Rightslink® by Copyright Clearance Center

First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease

Author:

Aina Bellver-Sanchis,David Valle-Garcia,Carla Barbaraci,Fernando Romero-Becerra,Rohit Kumar Singh,Júlia Jarne-Ferrer,Foteini Vasilopoulou,Alba Irisarri,Carmen Martínez-Fernández,Juan A. Fafián-Labora,María C. Arufe,Carolin Wüst,Aida Castellanos et al.

Publication:

Molecular Therapy

Publisher:

Elsevier

Date:

1 April 2026

Please select your organization and/or account

Organization

Account

Please select your account from the above dropdown list. These accounts represent the offices, campuses, and other sites where your organization operates. Your account selection should match where you typically have an office or workspace. Even when you are traveling or temporarily working elsewhere, you should select the account that represents where you customarily work.

Cancel OK